• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 88 of 100
MSMB Capital Management CIO Martin Shkreli
HealthTuring Says it Will Lower Daraprim Price by the End of the Year
By Laura LorenzettiNovember 4, 2015
Fortune Global Forum 2015
HealthHow the U.S. Subsidizes Europe’s Health Care Costs
By Beth KowittNovember 3, 2015
Hedge fund manager Bill Ackman
FinanceBill Ackman on Valeant: ‘Life will go on’
By Stephen GandelOctober 30, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant cuts ties to controversial pharmacy chain Philidor
By Geoffrey SmithOctober 30, 2015
Hedge fund manager Bill Ackman
FinanceAnother one of Bill Ackman’s top stocks is down 50%
By Jen WiecznerOctober 29, 2015
A Starbucks cafe in Sanlitun. For the third quarter of 2015
FeaturesPharma megadeal and Starbucks earnings — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithOctober 29, 2015
Allergan Inc.'s Botox Cosmetic As Actavis Plc Buys Drugmaker For $66 Billion
HealthWhen Viagra met Botox: Pfizer, Allergan eye mega-merger
By Geoffrey SmithOctober 29, 2015
Cholesterol lowering pill
HealthThis drug will make your flu shot less effective
By TIMEOctober 29, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant accounting scandal: 4 critical questions that have been left unanswered
By Stephen GandelOctober 26, 2015
Why the drug price scandal won’t be enough to keep down prices
RetailWhy the drug price scandal won’t be enough to keep down prices
By Laura LorenzettiOctober 26, 2015
Imprimis Turing Drug
HealthThis company is offering a $1 alternative to Turing’s $750 drug
By Laura LorenzettiOctober 23, 2015
MSMB Capital Management CIO Martin Shkreli
HealthThis super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
FinanceValeant’s accounting problems: It gets worse
By Stephen GandelOctober 22, 2015
Big pharma won’t stay silent in drug pricing debate for long
HealthBig pharma won’t stay silent in drug pricing debate for long
By Erika FryOctober 22, 2015
1...
  • 86
  • 87
  • 88
  • 89
  • 90
...100
Most Popular
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250placeholder alt text
By Fortune EditorsApril 9, 2026
Investing
Mark Cuban admits he made a mistake letting go of the Mavericks: 'I don't regret selling. I regret who I sold to'placeholder alt text
By Fortune EditorsApril 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.